KUALA LUMPUR, July 24 (Bernama) -- Neuralstem Inc -- a biopharmaceutical company developing novel treatments for nervous system diseases -- announced some positive results in the treatment of Alzheimer´s disease.
This was disclosed in the presentation of data at the Alzheimer's Association International Conference in Chicago, Illinois.
The presentation demonstrated that oral administration of NSI-189 in a mouse model of Alzheimer´s disease (AD) leads to a significant amelioration and/or improvement in cognition measures and anxiety, a statement said.
Key findings from the study shows that treatment with NSI-189 significantly improved the learning ability measured by a simple task and improved performance on a test of short term memory (Novel Object Recognition).
The results also improved motor learning of AD mice as measured by performance on a Rotarod test and decreased anxiety levels in both AD mice and control mice as measured by an open field test.
"Data from this preclinical study suggest that NSI-189 may be able to mitigate or reverse the cognitive impact of Alzheimer´s disease, " said associate professor in the Department of Pathology at UC San Diego School of Medicine, Dr. Corinne Jolivalt.
The study carried out by Dr. Jolivalt´s laboratory at the University of California, San Diego involved the oral administration of NSI-189 to mice harboring gene changes that recreate symptoms of familial Alzheimer´s disease.
-- BERNAMA
No comments:
Post a Comment